Buy CJC-1295 + Ipamorelin 5+5mg UK | Research Grade

This vial contains two co-lyophilised research peptides: CJC-1295 (without DAC), a 30-amino-acid tetra-substituted GHRH analogue with extended half-life, and Ipamorelin, a pentapeptide selective growth hormone secretagogue receptor (GHSR) agonist. Combined, they form the most widely cited GHRH + GHRP research blend in the published growth-hormone literature, used to study additive and synergistic GH pulse amplitude in pituitary and somatotroph cell models.

CJC-1295 binds the GHRH receptor on pituitary somatotrophs, increasing baseline GH pulse amplitude. Ipamorelin binds the separate ghrelin/GHSR receptor, triggering a complementary GH release pulse without significantly affecting prolactin, ACTH or cortisol — a notable selectivity advantage over older GHRPs such as GHRP-6. Combining the two engages both upstream pathways simultaneously, producing a larger and more physiological GH research signal than either peptide alone.

Published research using CJC-1295 and Ipamorelin individually or in combination covers somatotroph signalling and GH pulse studies, IGF-1 axis modulation, in-vitro pituitary cell research, sleep architecture and slow-wave sleep modelling, body composition research in animal models, recovery and tissue repair studies, and comparative pharmacology against other GHRH analogues (sermorelin, tesamorelin) and GHRPs (hexarelin, GHRP-2, GHRP-6).

Store the lyophilised vial at -20°C, sealed and protected from light. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) — typically 2ml per 10mg blend. Add solvent down the side of the vial; do not shake. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Both peptides in the blend remain stable in solution under refrigeration; do not refreeze.

The Certificate of Analysis for this blend reports HPLC-UV purity and mass-spectrometry identity for CJC-1295 and Ipamorelin as separate analytical entries, each verified to ≥98% purity. Janoshik Analytical or Aspen Bioanalytics signs each batch CoA. The lot number on the vial sticker matches the CoA exactly — co-lyophilised vials are not pooled or relabelled.

Co-lyophilised blends are particularly vulnerable to substitution and under-dosing on the grey market because the analytical separation requires more sophisticated HPLC method development than a single-peptide vial. Peptides UK addresses this with two-component independent verification on every lot, UK stock, same-day Manchester dispatch and full lot traceability.